The Rise of Population Genomic Screening: Characteristics of Current Programs and the Need for Evidence Regarding Optimal Implementation.
J Pers Med
; 12(5)2022 Apr 26.
Article
in En
| MEDLINE
| ID: mdl-35629115
ABSTRACT
PURPOSE:
Advances in clinical genomic sequencing capabilities, including reduced costs and knowledge gains, have bolstered the consideration of genomic screening in healthy adult populations. Yet, little is known about the existing landscape of genomic screening programs in the United States. It can be difficult to find information on current implementation efforts and best practices, particularly in light of critical questions about equity, cost, and benefit.METHODS:
In 2020, we searched publicly available information on the Internet and the scientific literature to identify programs and collect information, including setting, program funding, targeted population, test offered, and patient cost. Program representatives were contacted throughout 2020 and 2021 to clarify, update, and supplement the publicly available information.RESULTS:
Twelve programs were identified. Information was available on key program features, such as setting, genes tested, and target populations. Data on costs, outcomes, or long-term sustainability plans were not always available. Most programs offered testing at no or significantly reduced cost due to generous pilot funding, although the sustainability of these programs remains unknown. Gene testing lists were diverse, ranging from 11 genes (CDC tier 1 genes) to 59 genes (ACMG secondary findings list v.2) to broad exome and genome sequencing. This diversity presents challenges for harmonized data collection and assessment of program outcomes.CONCLUSIONS:
Early programs are exploring the logistics and utility of population genomic screening in various settings. Coordinated efforts are needed to take advantage of data collected about uptake, infrastructure, and intervention outcomes to inform future research, evaluation, and program development.
Full text:
1
Database:
MEDLINE
Type of study:
Diagnostic_studies
/
Guideline
/
Prognostic_studies
/
Screening_studies
/
Sysrev_observational_studies
Language:
En
Journal:
J Pers Med
Year:
2022
Type:
Article
Affiliation country:
United States